No Detail Found!

Effectiveness of Sofosbuvir and Velpatasvir Combination in Chronic Hepatitis C with Hemodialysis Patients

Author(s)
RAHMAT ALI KHAN Department, Nawaz Sharif Kidney Hospital,Swat, Pakistan
ANWAR ALI Saidu Group of Teaching Hospitals,Swat, Pakistan
SYED MUNIB Institute of Kidney Diseases (IKD),Peshawar, Pakistan
IFTIKHAR MUHAMMAD District Medical Specialist District Headquarters Hospital Batkhela,District Malakand, Pakistan
NOSHERWAN Department Lady Reading Hospital,Peshawar, Pakistan
AMJAD ALI Department Mardan Medical Complex,Mardan, Pakistan
Abstract
Objective: The aim of this study is to determine the response of sofosbuvir and velpatasvir combination in chronic hepatitis C with hemodialysis patients. Study Design: Prospective/observational study Place and Duration: The study was conducted at department of Nephrology Nawaz Sharif Kidney Hospital, Swat for duration of six months from 1st July to 31st December, 2020. Methods: Total 27 patients of both genders were presented in this study. Patients were aged between 18-85 years. Patients details demographics age, sex and body mass index were recorded after taking written consent. Patients diagnosis hepatitis C with recognized genotypes were presented. Enrolled patients received combination of sofosbuvir and velpatasvir regime (SOF/VLP) for 14 weeks and follow up was taken. Effectiveness and safety among HCV patients on hemodialysis were observed. Complete data was analyzed by SPSS 22.0 version. Results: Out of 27 patients 17 (62.96%) were males 10 (37.04%) were females. Mean age of the patients was 35.14±5.18 years with mean BMI 24.41±6.25 kg/m2. Hypertension was the most common comorbidity found in 15 (55.55%) patients followed by obesity 8 (29.63%) and diabetes found in 3 (14.81%). Among 27 cases 20 (74.04%) were naïve and 7 (25.96%) were treatment experienced. Sustained virological response was found in 26 (96.3%) and 1(3.7%) patients were lost at follow up. Significantly improvement was found in hemoglobin level 12.11 ± 5.24, alanine aminotransferase (ALT) 28.51 ± 9.62 and aspartate aminotransferase (AST) 35.24 ± 7.08 after treatment. Headache, fatigue and nausea were the most common adverse outcomes. Conclusion: We concluded in this study that the use of sofosbuvir and velpatasvir was effective safe and well tolerated in the treatment of hepatitis C patients with hemodialysis.
Publication Details
Page(s) 1205-1207
Published Journal: Pakistan Journal of Medical and Health Sciences, Volume: 15, Issue: 5, Year: 2021

Request the full text from PASTIC

Keywords
Complications, Hepatitis C, Sofosbuvir, Hemodialysis, Velpatasvir
0

Citations

0

Downloads

55

Views